A common solution to group 2 influenza virus neutralization

Proceedings of the National Academy of Sciences of the United States of America
Robert H E FriesenIan A Wilson

Abstract

The discovery and characterization of broadly neutralizing antibodies (bnAbs) against influenza viruses have raised hopes for the development of monoclonal antibody (mAb)-based immunotherapy and the design of universal influenza vaccines. Only one human bnAb (CR8020) specifically recognizing group 2 influenza A viruses has been previously characterized that binds to a highly conserved epitope at the base of the hemagglutinin (HA) stem and has neutralizing activity against H3, H7, and H10 viruses. Here, we report a second group 2 bnAb, CR8043, which was derived from a different germ-line gene encoding a highly divergent amino acid sequence. CR8043 has in vitro neutralizing activity against H3 and H10 viruses and protects mice against challenge with a lethal dose of H3N2 and H7N7 viruses. The crystal structure and EM reconstructions of the CR8043-H3 HA complex revealed that CR8043 binds to a site similar to the CR8020 epitope but uses an alternative angle of approach and a distinct set of interactions. The identification of another antibody against the group 2 stem epitope suggests that this conserved site of vulnerability has great potential for design of therapeutics and vaccines.

References

Aug 31, 2000·Annual Review of Biochemistry·J J Skehel, D C Wiley
Sep 29, 2001·Journal of Applied Microbiology·C W Potter
Jul 12, 2002·Vaccine·Walter R Dowdle
Jul 12, 2002·Vaccine·John J Skehel, Don C Wiley
Sep 5, 2002·Nature Reviews. Immunology·Dennis R Burton
Aug 28, 2007·Vaccine·F Carrat, A Flahault
Apr 17, 2008·Proceedings of the National Academy of Sciences of the United States of America·Arun K KashyapRichard A Lerner
Jan 13, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Iain StephensonMaria Zambon
Feb 24, 2009·Nature Structural & Molecular Biology·Jianhua SuiWayne A Marasco
Mar 3, 2009·Science·Damian C EkiertIan A Wilson
Apr 15, 2010·The Journal of Clinical Investigation·Davide CortiAntonio Lanzavecchia
Jan 12, 2011·The Journal of Experimental Medicine·Jens WrammertPatrick C Wilson
Jul 9, 2011·Science·Damian C EkiertJaap Goudsmit
Aug 10, 2011·Proceedings of the National Academy of Sciences of the United States of America·James R R WhittleStephen C Harrison
Aug 11, 2011·PloS One·Ramy ArnaoutSergei B Koralov
Nov 9, 2011·Journal of Molecular Biology·Mihai L AzoiteiWilliam R Schief
Apr 10, 2012·Current Opinion in Virology·Damian C Ekiert, Ian A Wilson
Aug 11, 2012·Science·Cyrille DreyfusRobert H E Friesen
Oct 3, 2012·Proceedings of the National Academy of Sciences of the United States of America·Peter S LeeIan A Wilson
Oct 11, 2012·Immunological Reviews·Jean-Philippe JulienIan A Wilson
Nov 24, 2012·Proceedings of the National Academy of Sciences of the United States of America·Aaron G SchmidtStephen C Harrison
Feb 12, 2013·Nature Structural & Molecular Biology·Rui XuIan A Wilson
May 28, 2013·Nature Structural & Molecular Biology·Leopold KongIan A Wilson

❮ Previous
Next ❯

Citations

Sep 8, 2015·Vaccines·Lidewij C M WiersmaRory D de Vries
Sep 10, 2014·Viruses·Yo Han Jang, Baik Lin Seong
Jul 16, 2015·Expert Review of Vaccines·Adam Kenneth Wheatley, Stephen John Kent
Feb 13, 2016·Immunological Reviews·Mark J KwakkenbosHergen Spits
Mar 26, 2016·Biomicrofluidics·Samaneh Mashaghi, Antoine M van Oijen
Mar 2, 2016·Current Opinion in Virology·Florian Krammer
Mar 30, 2016·The Journal of Experimental Medicine·Rino RappuoliEnnio De Gregorio
Aug 26, 2015·Science·Antonietta ImpagliazzoKatarina Radošević
Jun 7, 2015·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Peter C SoemaGideon F A Kersten
Jun 4, 2014·Biochimica Et Biophysica Acta·Ujjwal RathoreRaghavan Varadarajan
Apr 8, 2015·Current Opinion in Virology·Gillian M Air
Sep 12, 2014·Journal of Bioinformatics and Computational Biology·Jing RenJinyan Li
Feb 18, 2015·The Journal of Clinical Investigation·Carole J Henry DunandPatrick C Wilson
Mar 19, 2015·BioMed Research International·Anwar M Hashem
Nov 12, 2014·Proceedings of the National Academy of Sciences of the United States of America·Koen WagnerHergen Spits
Oct 30, 2016·Current Opinion in Immunology·Karlynn E NeuPatrick C Wilson
Oct 30, 2016·Current Opinion in Immunology·Huanhuan Ren, Paul Zhou
Jul 28, 2016·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy·Nachiket ShembekarSatish Kumar Gupta
Sep 21, 2016·Proceedings of the National Academy of Sciences of the United States of America·Paul E LeonGene S Tan
May 6, 2017·Viruses·Elma Tchilian, Barbara Holzer
Dec 3, 2016·Nature Communications·Wenshuai WangBing Sun
Oct 9, 2014·Nature·Marie PanceraPeter D Kwong
Aug 28, 2018·Expert Review of Vaccines·Federica SiccaAnke Huckriede
Sep 12, 2014·Journal of Virology·Raffael NachbagauerFlorian Krammer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.